Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (221-230 of 272) with videos related to

Pageof 28
Sort By:
Kidney International Reports|May 14, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT StudyJonathan Barratt, Brad Rovin, Muh Geot Wong, et al.
Kidney International|June 6, 2024
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceMarina Vivarelli, Jonathan Barratt, Laurence H Beck, et al.
Nature Communications|January 28, 2023
Next-Generation Morphometry for pathomics-data mining in histopathologyDavid L Hölscher, Nassim Bouteldja, Mehdi Joodaki, et al.
Kidney International Reports|May 20, 2024
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX StudyHoward Trachtman, Jai Radhakrishnan, Michelle N Rheault, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 13, 2019
Proteinuria Reduction as a Surrogate End Point in Trials of IgA NephropathyAliza Thompson, Kevin Carroll, Lesley A Inker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
Journal of the American Society of Nephrology : JASN|March 29, 2026
Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover TrialHiddo J L Heerspink, Irene L Noronha, Jose Luis Górriz, et al.
BMJ Open|October 6, 2021
A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methodsRoseanne E Billany, Noemi Vadaszy, Nicolette C Bishop, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2016
A Multicenter Study of the Predictive Value of Crescents in IgA NephropathyMark Haas, Jacobien C Verhave, Zhi-Hong Liu, et al.
Journal of Medical Internet Research|November 14, 2022
The Codevelopment of "My Kidneys & Me": A Digital Self-management Program for People With Chronic Kidney DiseaseCourtney J Lightfoot, Thomas J Wilkinson, Michelle Hadjiconstantinou, et al.
Pageof 28

Showing results (221-230 of 272) with videos related to

Sort By:
Pageof 28
Kidney International Reports|May 14, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT StudyJonathan Barratt, Brad Rovin, Muh Geot Wong, et al.
Kidney International|June 6, 2024
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceMarina Vivarelli, Jonathan Barratt, Laurence H Beck, et al.
Nature Communications|January 28, 2023
Next-Generation Morphometry for pathomics-data mining in histopathologyDavid L Hölscher, Nassim Bouteldja, Mehdi Joodaki, et al.
Kidney International Reports|May 20, 2024
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX StudyHoward Trachtman, Jai Radhakrishnan, Michelle N Rheault, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 13, 2019
Proteinuria Reduction as a Surrogate End Point in Trials of IgA NephropathyAliza Thompson, Kevin Carroll, Lesley A Inker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 11, 2026
Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION TrialKieran McCafferty, Jonathan Barratt, Yusuke Suzuki, et al.
Journal of the American Society of Nephrology : JASN|March 29, 2026
Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover TrialHiddo J L Heerspink, Irene L Noronha, Jose Luis Górriz, et al.
BMJ Open|October 6, 2021
A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methodsRoseanne E Billany, Noemi Vadaszy, Nicolette C Bishop, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2016
A Multicenter Study of the Predictive Value of Crescents in IgA NephropathyMark Haas, Jacobien C Verhave, Zhi-Hong Liu, et al.
Journal of Medical Internet Research|November 14, 2022
The Codevelopment of "My Kidneys & Me": A Digital Self-management Program for People With Chronic Kidney DiseaseCourtney J Lightfoot, Thomas J Wilkinson, Michelle Hadjiconstantinou, et al.
Pageof 28